Elevai Labs Inc. (NASDAQ: ELAB) specializes in medical aesthetics and biopharmaceutical drug development, focusing on aesthetic innovations for skin, and treatments tied to obesity and metabolic health. Driven by a commitment to scientific research, we aim to transform personal health and beauty.
Elevai Skincare Inc., an Elevai Labs company, is a medical aesthetics company developing and commercializing cutting-edge physician-dispensed skin and hair care applications. Elevai develops cosmetic products for the physician-dispensed market, with a focus on leveraging novel proprietary science-backed technologies, including its stem cell exosome technology.
ELEVAI Skincare™ products were developed under a proprietary “source to skin” technology platform called PREx, Precision Regenerative Exosome Technology™. PREx is based on over 15 years of research and development by stem cell expert and biochemical engineer, Dr. Jordan Plews.
The ELEVAI E-Series™ products, empower and enfinity, were developed to provide both post-treatment skin support and ongoing daily aftercare. Both products contain exosomes; ultra-small, nanoparticle compartments packed with growth factors known to support skin health. The patent pending ELEVAI Exosome™ is the powerhouse ingredient in all ELEVAI products and mimics the elegant repair process of nature along with a selection of high-quality actives to provide ongoing skin health for any skin type.
ELEVAI Skincare products are available in Dermatology, Plastic Surgery, and Professional Medical Spa locations across the US, Canada, and other international markets. We expect continued growth across all markets in 2023-24.
Elevai Biosciences Inc., an Elevai Labs company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Our lead asset, EL-22, is leveraging a first-in-class engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. EL-22 has completed a Phase 1 clinical trial in South Korea, demonstrating it was generally well tolerated and safe in healthy volunteers. Elevai intends to evaluate EL-22 for efficacy and safety in combination with popular weight-loss therapeutics currently on the market, with the goal of decreasing fat mass while preventing the muscle wasting that commonly occurs with weight-loss drugs. This asset, along with EL-32, a preclinical engineered probiotic expressing dual myostatin & activin-A, were licensed from our Korean partner.
Elevai Skincare
With the discovery of exosome technology and the recent advancement of this research in topical skincare applications, ELEVAI will lead the way by bringing PREx Technology to the professional skincare market revolutionizing how skin concerns related to aging and overall longevity of skin are addressed.
At ELEVAI® we believe this is the future of skincare and skin wellness and we believe that we have the right people, the right technology, and the right timing to take the industry by storm and provide both physicians and consumers with next-generation products that are science-driven, efficacious, and at the leading edge of innovation.
Elevai Biosciences
Currently, more than 40% of adults in the United States live with obesity — a figure predicted to rise to 50% by 2030. Obesity is a leading risk factor for the development of serious health conditions, including Type 2 diabetes and heart failure. Goldman Sachs predicts that this epidemic will create a $100 billion market for anti-obesity players.
Approved GLP-1 drugs used in weight loss, such as Novo Nordisk’s Ozempic® (semaglutide) & Wegovy®(semaglutide) and Eli Lilly’s Zepbound (tirzepatide), and Mounjaro® (tirzepatide) have transformed the obesity treatment landscape. However, past studies of these highly effective drugs show that up to 40% of the weight loss is due to loss of lean muscle. Physicians have expressed concern around this problematic finding as muscle is necessary for metabolism, strength, and physical function. As a result, one of the key unmet needs in the current obesity landscape is the avoidance of muscle loss while on weight loss treatments.
Elevai is developing EL-22, an engineered probiotic with myostatin antigens, to elicit an immune response that could help people achieve substantial fat loss without losing muscle mass.
